Was ist mit Xoma - 500 Beiträge pro Seite

[milkon11]

Was ist mit Xoma(871239)???????
Was ist denn da los?


Weiß jemand was näheres?

[BigLinus]

XOMA Announces Webcast of Presentation at the U.S. Bancorp Piper Jaffray Health Care Conference
BERKELEY, Calif.--(BW HealthWire)--Jan. 25 2002--XOMA Ltd. (Nasdaq:XOMA - news), announced today that an audio version of its presentation at the U.S. Bancorp Piper Jaffray Health Care Conference will be webcast live on Wednesday, January 30th at 4:00 pm (Eastern Time).

Jack Castello, XOMA`s chief executive officer, will provide an overview of recent business developments, including an update on the status of XOMA`s development pipeline. The presentation will be delivered at 4:00 p.m. (Eastern Time) from the Pierre Hotel in New York. A webcast version of the presentation will be available via a link on the XOMA website at www.xoma.com. The webcast will be archived for thirty days following the presentation.

Ciao BigLinus

[BigLinus]

XOMA Presents Corporate Update At U.S. Bancorp Conference
Highlights Include Plans For Phase II Study Of Efalizumab (anti-CD11a) In Rheumatoid Arthritis
BERKELEY, Calif.--(BW HealthWire)--Jan. 30, 2002-- XOMA Ltd. (Nasdaq:XOMA - news) announced today that Jack Castello, XOMA`s Chairman, President, and CEO, provided an overview of recent business developments, including an update on key advancements in XOMA`s development pipeline.

Mr. Castello presented to a group of investors attending the U.S. Bancorp Piper Jaffray Healthcare Conference at the Pierre Hotel in New York. A webcast version of the presentation is available via a link on the XOMA website at www.xoma.com. The webcast will be archived for thirty days following the presentation.

Highlights of the presentation included the following:

In collaboration with Genentech, Inc., XOMA plans to conduct a Phase II clinical study of Efalizumab (anti-CD11a) in rheumatoid arthritis. The randomized, placebo controlled, double-blinded study plans to enroll more than 300 patients at multiple centers. The study will evaluate the efficacy and safety of Efalizumab, a recombinant, humanized monoclonal antibody designed to selectively inhibit immune system T cells.
Rheumatoid arthritis is the third indication being evaluated for this investigational antibody. A Phase I/II study in organ transplant patients was initiated in March of 2000 and a Biologics License Application (BLA) filing is anticipated in the summer of 2002 for Xanelim(TM) (Efalizumab) in patients with moderate-to-severe plaque psoriasis.
Preliminary financial results indicate that the Company`s net loss per share was in line with analyst projections of ($0.10) for the fourth quarter. Preliminarily, the company estimates a net loss per share of ($0.41) for the full year ended December 31, 2001. With $67 million in cash, cash equivalents and short-term investments, the Company estimates its cash resources to be sufficient to fund its anticipated operational needs through at least mid-2004.

[BigLinus]

Hi XOMA-Fans,

XOMA hat die Analysten-Prognosen für das 4. Quartal 2001 erfüllt und wird für das gesamte abgelaufene Jahr über den Erwartungen liegen. Das Unternehmen sieht sich aufgrund der Cash-Reserven bis Mitte 2004 durchfinanziert.

Für den Sommer 2002 erwartet XOMA die Einreichung des Zulassungsantrages für das Psoriasis-Medikament `Xanelim`, das gemeinsam mit Genentech entwickelt wurde.

Dies und die wohl positive Darstellung auf der Healthcare Conference der letzten Woche, hat das Analystenteam von Adams Harkness dazu animiert XOMA von BUY auf STRONG BUY hochzustufen.

Ciao BigLinus

[BigLinus]

Hi XOMA-Fans,

hier eine Meldung von letzter Woche, die das Interesse an XOMA nicht gerade steigern wird:


Thursday February 14, 1:54 pm Eastern Time
Biosite shares up 26 pct on new antibody technology
LOS ANGELES, Feb 14 (Reuters) - Shares of Biosite Inc. (NasdaqNM:BSTE - news) rose 26 percent on Thursday after the developer of diagnostic and drug-discovery tests said new technology will allow it to stop licensing patents from a competitor.

Shares of the San Diego-based company were up $3.69 at $17.79 in Thursday afternoon trading on Nasdaq.

Biosite said it is implementing new antibody expression technology intended to allow it to operate its business without using patents licensed from Xoma Ltd. (NasdaqNM:XOMA - news), a biotechnology company based in Berkeley, California, that last year claimed Biosite was in breach of the license agreements. Since then, the two companies have been embroiled in litigation.

Biosite said last year that the license lawsuit had interfered with deliveries to its antibody development and diagnostic marker discovery customers. The company said the new technology is being incorporated in its ``Omniclonal`` system used by drug researchers to detect and develop antibodies.

``We have designed our own novel antibody expression technology that is fundamentally different than that at the center of our dispute with Xoma,`` Gunars Valkirs, vice president Biosite Discovery, said in a statement.

By the end of the year, Biosite said it expects that all recombinant antibodies used in its diagnostic products will be produced using the new technology.

The company said it has filed a patent application for the new technology and will license it to other companies.

Ciao BigLinus